Trade Analytics

Sun Pharmaceuticals

Go Back

Sun Pharmaceuticals

  • Leading pharma company in India in 2017 as per Moving Annual Turnover (MAT)
  • World's fifth largest specialty generic pharmaceutical company
  • Serves over 150 markets across the world
  • More than 2,000 marketed products
  • More than 40 manufacturing sites

Sun Pharmaceuticals is the largest pharmaceutical company from India and the fifth largest specialty generic company in the world. It has capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets and capsules. Its businesses include producing generics, branded generics, speciality, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates in the full range of dosage forms. It also produces specialty APIs. US formulations contributed the most to company’s US$ 4 billion sales in FY18 with a contribution of 34 per cent, followed by India branded formulations at 31 per cent. In FY19, total income of the company reached Rs 30,091.40 crore (US$ 4.33 billion).

Company Website:

Sun Pharma – Reaching People. Touching Lives.

2018 Sales of Rs 27,956 crore (US$ 4 billion) in FY18; Announced acquisition of US-based speciality pharmaceutical company Avenue Therapeutics for Rs 1502.635 crore (US$ 215 million)
2017 Agreement signed with National Institute of Virology, India to fight Zika, Chikungunya and Dengue
2013 Became world’s fifth largest specialty generic pharmaceutical company with acquisition of Ranbaxy
2000 Acquired Pradeep Drug Company
1997 First international acquisition with Caraco Pharmaceutical Laboratories, USA
1996 Sales network expanded across 24 countries
1994 Launched initial public offer (IPO)
1989 Introduced gastroenterology products in India
1983 Established with a portfolio of five psychiatry products


Updated: May, 2019

The exports are expected to reach US$ 20 billion by 2020.